Analysis of Synthetic Cannabinoids Using Ion Mobility Enabled High-Resolution Mass Spectrometry

Importance of the topic

Synthetic cannabinoids are continually evolving psychoactive substances designed to mimic THC, often with greater potency. Their structural diversity and rapid emergence pose significant challenges for accurate identification in forensic and analytical laboratories. Incorporating collision cross section (CCS) measurements via ion mobility spectrometry (IMS) into high-resolution mass spectrometry workflows offers an additional separation dimension to enhance compound specificity and reduce false positives.

Study objectives and overview

This study evaluated the feasibility of using CCS data to distinguish two isomeric synthetic cannabinoids, JWH-015 and JWH-073, which share identical elemental composition and closely elute in chromatographic analyses. The goal was to determine whether CCS values could serve as reliable markers for unambiguous isomer differentiation.

Methodology and instrumentation

• Sample preparation: Individual stock solutions (1 mg/mL) were diluted to 100 ng/mL with mobile phase.
• Chromatography: Waters ACQUITY UPLC I-Class system employing a published method for cannabinoid separation.
• Mass spectrometry: Waters Vion IMS QTof in high-definition MSE mode collected accurate mass and IMS drift time data.
• Data processing: Waters UNIFI Scientific Information System matched retention time (±0.35 min), accurate mass (±5 ppm), and CCS (±1%) against a reference library.

Main results and discussion

Both JWH-015 and JWH-073 produced isobaric precursor ions (m/z 328.1696) and identical high-energy fragment ions, co-eluting at ~11.85–11.90 min. Measured CCS values were highly reproducible and distinct: 178.93 Ų for JWH-015 and 182.66 Ų for JWH-073. IMS mobilograms of the mixture confirmed different drift times driven by subtle conformational differences, enabling clear separation despite chromatographic overlap.

Benefits and practical applications

Integrating CCS measurements into screening workflows:

• Provides an orthogonal separation parameter to resolve isomers.
• Enhances library-based identification specificity.
• Reduces false positive rates by filtering interfering ions.
• Facilitates more reliable forensic and toxicological analyses.

Future trends and opportunities

Expanding the application of IMS-enabled CCS analysis may include:

• Building comprehensive CCS databases for novel psychoactive substances.
• Standardizing CCS measurements across laboratories.
• Automating high-throughput screening in QA/QC environments.
• Combining IMS-HRMS with machine learning for pattern recognition.

Conclusion

This study demonstrates that CCS data from IMS-enabled high-resolution MS can unambiguously differentiate isomeric synthetic cannabinoids. The approach adds critical selectivity to traditional mass and retention time metrics, supporting broader adoption in analytical and forensic laboratories.

References

1. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA website (accessed 13 Sept 2016).
2. Rosano TG, Wood M, Ihenetu K, Swift TA. Drug Screening in Medical Examiner Casework by High-Resolution Mass Spectrometry (UPLC–MSE TOF). Journal of Analytical Toxicology. 2013.
3. Mistry NS, Wilson S, Wood M. Evaluation of an Ion Mobility-MS Approach for Toxicology Screening. Poster at The International Association of Forensic Toxicologists, Brisbane. 2016.